It is a novel siRNA-based anti-HBV therapeutic which is being developed by Biomics. It consists of two components:
Biomics has completed high-throughput target siRNA screening in vitro and discovered five novel siRNA sequences that are highly effective against the four major HBV subtypes (Figure 3.2). Biomics’ preliminary data has shown that theMultisiRNA design is effective and safe in both in vitro and early stage in vivo studies (in an HBV-infected mouse model).
The efficacy of the approach has been demonstrated against subtype D using one of the identified sequences targeting the HBV polymerase gene, and the Company is ready to expand its studies to subtypes A, B and C. The Company’s goal is to validate the efficacy in vivo for all four subtypes. Further evaluation and optimisation is needed to confirm the optimal siRNA drug candidates to achieve this.
The Company also has generated in vivo data demonstrating the safety of the new generation LNP delivery vehicle. Further development is being undertaken to ensure compatibility with the multi-target siRNAs.
When the preclinical development program is complete, Biomics plans to commence clinical studies in China and Australia.